Application Note

Optimization And Scale-Up Of siRNA Synthesis

Source: Cytiva
OptimizationAndScaleUp

The latest “trend” in oligonucleotide therapeutics is the development of therapeutic siRNA molecules. As its name suggests, RNA interference (RNAi) is a cellular mechanism regulating the expression of genes and also the replication of viruses. The mechanism is mediated by double-stranded small interfering RNA molecules (siRNA). Discovered in 1998, siRNA is the latest biotechnology breakthrough that raises hopes for discovery of the “magic bullet” that would allow the specific targeting of any disease-relevant gene. In theory, siRNA therapeutics can be 100% specific for a particular gene, because the sequences can be selected to interact with one particular mRNA only. Only 6 years after discovery of the therapeutic opportunities in siRNA molecules, two companies, Sirna and Acuity Pharmaceuticals, have already entered clinical trials with siRNA compounds targeted against vascular endothelial growth factor (VEGF) for treatment of age-related macular degeneration (AMD).

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: